Larimar Therapeutics – FA trial update - Ataxia UK

Larimar Therapeutics – FA trial update

Post Published: April 13, 2023

Larimar Therapeutics is a biotechnology company, developing a treatment for Friedreich’s ataxia (FA) called CTI-1601. CTI-1601 replaces frataxin, which is the protein that is reduced in FA.

Larimar Therapeutics recently announced that the first cohort for their Phase 2 trial has enrolled all participants, and is proceeding as planned. This 4 week trial is designed to identify the best dose of CTI-1601. They expect to provide an update on this trial later this year, when their data has been reviewed by the US regulators (the FDA).

This Phase 2 trial is taking place in the US.

For more information, read the full press release.

Subscribe To Our Newsletter

fundraise image


Take part in a challenge or create your fundraiser. Every penny you raise will help those affected by ataxia.

Donate Image


To make either a one off or recurring donation which will help fund research into treatments and cures and supports those affected ataxia

Volunteer Image


Support the ataxia community and volunteer with Ataxia UK. From social media to telephone befriending, there are loads of ways you can make a difference to someone's life.

Donate Now
Scroll to Top